Relapsed childhood acute lymphoblastic leukemia in the Nordic countries:Prognostic factors, treatment and outcome by Oskarsson, Trausti et al.
Syddansk Universitet
Relapsed childhood acute lymphoblastic leukemia in the Nordic countries
Prognostic factors, treatment and outcome
Oskarsson, Trausti; Söderhäll, Stefan; Arvidson, Johan; Forestier, Erik; Montgomery, Scott;
Bottai, Matteo; Lausen, Birgitte; Carlsen, Niels; Hellebostad, Marit; Lähteenmäki, Päivi;
Saarinen-Pihkala, Ulla M; Jónsson, Ólafur G.; Heyman, Mats; on behalf of the Nordic Society
of Paediatric Haematology; and Oncology (NOPHO) ALL relapse working group
Published in:
Haematologica
DOI:
10.3324/haematol.2015.131680
Publication date:
2016
Document version
Publisher's PDF, also known as Version of record
Citation for pulished version (APA):
on behalf of the Nordic Society of Paediatric Haematology, & and Oncology (NOPHO) ALL relapse working
group (2016). Relapsed childhood acute lymphoblastic leukemia in the Nordic countries: Prognostic factors,
treatment and outcome. Haematologica, 101(1), 68-76. DOI: 10.3324/haematol.2015.131680
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 09. Sep. 2018
68 haematologica | 2016; 101(1)
Received: 4/6/2015. 
Accepted: 20/10/2015.
Pre-published: 22/10/2015.
©2016 Ferrata Storti Foundation
Check the online version for the most updated
information on this article, online supplements,
and information on authorship & disclosures:
www.haematologica.org/content/101/1/68
Material published in Haematologica is cov-
ered by copyright. All rights reserved to Ferrata
Storti Foundation. Copies of articles are
allowed for personal or internal use. A permis-
sion in writing by the publisher is required for
any other use.
Correspondence: 
trausti.oskarsson@ki.se
Relapse is the main reason for treatment failure in childhood acutelymphoblastic leukemia. Despite improvements in the up-fronttherapy, survival after relapse is still relatively poor, especially for
high-risk relapses. The aims of this study were to assess outcomes fol-
lowing acute lymphoblastic leukemia relapse after common initial Nordic
Society of Paediatric Haematology and Oncology protocol treatment; to
validate currently used risk stratifications, and identify additional prog-
nostic factors for overall survival. Altogether, 516 of 2735 patients
(18.9%) relapsed between 1992 and 2011 and were included in the study.
There were no statistically significant differences in outcome between
the up-front protocols or between the relapse protocols used, but an
improvement over time was observed. The 5-year overall survival for
patients relapsing in the period 2002-2011 was 57.5±3.4%, but
44.7±3.2% (P<0.001) if relapse occurred in the period 1992-2001. Factors
independently predicting mortality after relapse included short duration
of first remission, bone marrow involvement, age ten years or over, unfa-
vorable cytogenetics, and Down syndrome. T-cell immunophenotype
was not an independent prognostic factor unless in combination with
hyperleukocytosis at diagnosis. The outcome for early combined pre-B
relapses was unexpectedly poor (5-year overall survival 38.0±10.6%),
which supports the notion that these patients need further risk adjust-
ment. Although survival outcomes have improved over time, the devel-
opment of novel approaches is urgently needed to increase survival in
relapsed childhood acute lymphoblastic leukemia. 
Relapsed childhood acute lymphoblastic
leukemia in the Nordic countries: prognostic
factors, treatment and outcome
Trausti Oskarsson,1,2 Stefan Söderhäll,1,2 Johan Arvidson,3 Erik Forestier,4 Scott
Montgomery,5-7 Matteo Bottai,8 Birgitte Lausen,9 Niels Carlsen,10 Marit
Hellebostad,11 Päivi Lähteenmäki,12 Ulla M. Saarinen-Pihkala,13 Ólafur
G.Jónsson,14 and  Mats Heyman1,2 on behalf of the Nordic Society of Paediatric
Haematology and Oncology (NOPHO) ALL relapse working group
1Department of Pediatric Oncology, Astrid Lindgren Children´s Hospital, Stockholm,
Sweden; 2Childhood Cancer Research Unit, Department of Women´s and Children´s
Health, Karolinska Institutet, Stockholm, Sweden; 3Department of Pediatric Oncology,
Uppsala University Hospital, Sweden; 4Department of Pediatrics, Umeå University
Hospital, Sweden; 5Clinical Epidemiology and Biostatistics, Faculty of Medicine and
Health, Örebro University, Sweden; 6Clinical Epidemiology Unit, Karolinska University
Hospital, Karolinska Institutet, Stockholm, Sweden; 7Department of Epidemiology and
Public Health, University College London, UK; 8Unit of Biostatistics, IMM, Karolinska
Institutet, Stockholm, Sweden; 9Department of Pediatric Oncology, Rigshospitalet
University Hospital, Copenhagen, Denmark; 10Department of Pediatrics, Odense
University Hospital, Denmark; 11Department of Pediatrics, Ullevål Hospital, Oslo, Norway;
12Department of Pediatrics, Turku University Hospital, Turku, Finland; 13Children's
Hospital, University of Helsinki and Helsinki University Central Hospital, Finland; 
and 14Children’s Hospital, Landspitali University Hospital, Reykjavik, Iceland
ABSTRACT
Ferrata Storti
Foundation
EUROPEAN
HEMATOLOGY
ASSOCIATION
Haematologica 2016
Volume 101(1):68-76
ARTICLE Acute Lymphoblastic Leukemia
doi:10.3324/haematol.2015.131680
Introduction 
With advances in chemotherapy, hematopoietic stem cell transplantation (HSCT)
and supportive care, long-term survival in childhood acute lymphoblastic leukemia
(ALL) is now 85-90%.1,2 Despite increasing concerns regarding treatment-related
mortality and second malignancies, the main reason for
treatment failure is still relapse.3 In the Nordic countries,
the relapse rate was close to 40% between 1981 and 1993
and only 30% remained in long-term second remission.4
Over the last two decades, the reported relapse rates have
been 15-20%1-3,5,6 in the developed countries and the over-
all survival after relapse approximately 40-70%, depend-
ing on the follow-up time and the risk groups involved.7-12
Since 1992, all children aged one year and over diag-
nosed with pre-B and T-cell ALL in the Nordic countries
(Denmark, Finland, Iceland, Norway, Sweden) have been
treated according to a common Nordic Society of
Paediatric Haematology and Oncology (NOPHO) ALL
protocol. Children with relapsed ALL, on the other hand,
have been treated heterogeneously since there has not
been a common NOPHO ALL relapse protocol. The most
commonly used relapse protocols have been the high-risk
(HR) arms of the NOPHO ALL-92 or ALL-2000 front-line
protocols, the German Berlin Frankfurt Münster (BFM)
ALL-REZ relapse protocols, and the Finnish Relapse in
Acute Lymphoblastic Leukemia (RALLE) pilot protocol,13
which was used mainly in Finland between 2004 and
2010. After 2009, the British Children´s Cancer and
Leukemia Group (CCLG) ALLR3 relapse protocol has also
been used in the Nordic countries, but the International
study for treatment of childhood Relapsed ALL
(IntReALL) trial is expected to replace other relapse proto-
cols in the near future. 
Risk stratification at relapse is based on the time from
initial diagnosis to relapse, the anatomic site of relapse,
and immunophenotype.10-14 In addition, the most recent
relapse protocols have integrated therapy response with
minimal residual disease (MRD) for further treatment
adjustments.9,11,15,16 But unlike risk stratification at primary
diagnosis, cytogenetic aberrations, including MLL
rearrangements17,18 and hypodiploidy,19,20 currently do not
directly modify relapse treatment intensity. Patients meet-
ing high-risk criteria at relapse are recommended to under-
go allogeneic HSCT in CR2, but the indication for HSCT
in patients with lower risk is still under dispute, although
in most centers patients with high MRD after convention-
al re-induction are candidates for allogeneic HSCT.8,21
Rigorous selection of patients for the most appropriate
treatment intensity is important not only to minimize the
risk of subsequent relapses but also to minimize treat-
ment-related toxicity and mortality.22-25 
Relatively few studies of the long-term outcome after
relapsed childhood ALL have been published. Our study
cohort is population-based and includes over 500 patients
treated according to common up-front protocols, making
it, to our best knowledge, the largest of its kind. We
hypothesize that thorough analysis of prognostic factors,
validation of the current risk stratification and comparison
of treatment modalities could be helpful in  improving
treatment for relapsed childhood ALL. 
Methods
Study population and data collection
Information on all children aged 1.0-14.9 years  at diagnosis
(n=2735) treated according to the NOPHO ALL-92 (n=1644) and
ALL-2000 (n=1091) protocols were extracted from the NOPHO
ALL registry and patients that relapsed before January 1st 2012
were identified. In 516 (18.9%) patients, relapse occurred as a pri-
mary event, in 339 (20.6%) after ALL-92 treatment, and in 177
(16.2%) following ALL-2000 treatment. In total, 130 (4.8%)
patients underwent allogeneic HSCT in CR1 of which 31 (23.8%)
relapsed. Since patients that relapse after HSCT in CR1 differ sub-
stantially from patients treated with chemotherapy only, in base-
line characteristics, treatment and outcome, they were excluded
from all outcome analysis. Thus this report includes the 485
relapse patients who did not receive HCST in CR1. The database
was frozen on the 31st of December 2013 and this dataset was
used for outcome analysis. In 95 patients for whom the registra-
tion of relapse treatment, therapy response, outcome or follow-up
status was incomplete, data were acquired from the treating hos-
pitals to supplement the registration. Data concerning genetic
aberrations were centrally reviewed by the NOPHO cytogenetic
group. Cytogenetic findings were divided into four groups.
Unfavorable: hypodiploidy (modal chromosomal number <45),
MLL rearrangements, t(9;22) BCR/ABL and t(1;19); Favorable: high
hyperdiploidy (modal chromosomal number >50) and t(12;21);
Other: iAMP21, dic(9;20), unspecified chromosomal abnormali-
ties; and Normal/missing: 46XX/XY or missing values. See Online
Supplementary Appendix for the definition of relapse and second
complete remission. This study was approved by the Ethical
Review Board in Stockholm and was conducted in accordance
with the Declaration of Helsinski.
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Table 1. Risk stratification by immunophenotype, the time from diagnosis to relapse and the anatomic site of relapse.
5y-OS ± s.e.% or Pre-B T-cell
alive/total iEM combined iBM iEM combined iBM
Very early n=9 n=4 n=50 n=18 n=10 n=12
6/9 0/4 22.0 ± 5.9% 27.8 ± 10.6% 30.0 ± 14.5% 8.3 ± 8.0%
Early n=44 n=21 n=67 n=3 n=3 n=8
76.0 ± 6.6% 38.0 ± 10.6% 36.6 ± 6.0% 1/3 0/3 4/8
Late n=24 n=43 n=155 n=2 n=1 n=3
82.0 ± 8.3% 77.4 ± 6.7% 60.3 ± 4.1% 1/2 1/1 1/3
Standard-risk group (in bold) and high-risk group (in italics) according to the IntReALL risk classification.  The boxes include the total number of patients and the overall survival
for each subgroup. For subgroups involving less than 10 patients, survival is presented as the proportion of patients alive within the subgroup at the end of the follow-up period
instead of 5-year overall survival (OS) (± standard error) (s.e.). Isolated extramedullary relapses (iEM): relapses not involving the bone marrow, such as the central nervous system
(CNS), testis, lymph nodes, mediastinum and skin. Combined relapses: co-existent bone marrow and extramedullary involvement. Isolated bone marrow relapses (iBM): bone mar-
row relapses without any extramedullary involvement. Very early relapses: occurring <18 months from primary diagnosis. Early relapses: occurring ≥18 months from diagnosis and
<6 months after completion of primary therapy. Late relapses: occurring ≥6 months after completion of primary therapy.  Eight patients with unknown immunophenotype were
excluded from the survival analysis; very early iBM = 1,  early iBM = 2, early iEM = 1, late iBM = 2, late iEM = 2. 
Treatment
A detailed description of the risk groups and treatment used in
the NOPHO ALL-92 and ALL-2000 protocols, as well as a compar-
ison of the long-term results of these up-front ALL treatments have
been published by Schmiegelow et al.1 We categorized the relapse
treatment into four groups: ALL-REZ BFM protocols (90, 95/96 and
2002), NOPHO ALL-92 and ALL-2000 HR arms used as relapse
therapy, RALLE pilot and “other treatment”. The “other treatment”
group included patients treated with combinations of protocols, the
CCLG ALLR3 relapse protocol, Children´s Cancer Group (CCG)
relapse protocols and non-protocol chemotherapy. None of the 5
patients with t(9;22) were treated with tyrosine kinase inhibitors.
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Table 2. Cox’s proportional hazards regression analysis of risk factors for overall survival after ALL relapse. 
Prognostic factors Unadjusted model Adjusted model 1 Adjusted model 2
N. HR (95% CI) HR (95% CI) HR (95% CI)
Very early relapse1 104 3.84 (2.82 – 5.24)*** 3.67 (2.56 – 5.26)*** 3.80 (2.64 – 5.48)***
Early relapse1 149 1.85 (1.37 – 2.51)*** 2.33 (1.70 – 3.19)*** 2.36 (1.73 – 3.24)***
Isolated bone marrow relapse2 300 1.91(1.33 – 2.73)*** 2.87 (1.97 - 4.19)*** 2.98 (2.04 – 4.35)***
Combined relapse2 82 1.47 (0.93 – 2.31) 2.22 (1.39 - 3.52)** 2.31 (1.45 – 3.68)***
T-cell ALL3 60 2.25 (1.61 – 3.13)*** 1.43 (0.97 - 2.11) -
WBC ≥ 100 x 109/L 72 1.70 (1.24 – 2.34)** 1.27 (0.69 - 1.79) -
at primary diagnosis4 -
Male5 314 0.96(0.74 - 1.24) 1.07 (0.82 - 1.41) 1.08 (0.82 – 1.42)
Age ≥ 10 years 97 1.76 (1.32 - 2.34)*** 1.73 (1.28 - 2.34)** 1.80 (1.33 – 2.44)***
at primary diagnosis6
Unfavorable cytogenetics7,* 28 2.55 (1.61 – 4.06)*** 1.86 (1.14 – 3.03)* 1.83 (1.12 – 2.98)*
Favorable cytogenetics7,* 173 0.80 (0.58 – 1.09) 1.05 (0.74 – 1.48) 1.05 (0.75 – 1.49)
Other cytogenetics7,* 123 1.18 (0.85 – 1.62) 1.08 (0.77 – 1.50) 1.15 (0.82 – 1.60)
Down syndrome8 17 2.07 (1.21 - 3.56)** 2.70 (1.51 – 4.82)** 2.63 (1.48 – 4.70)**
T-cell + WBC  ≥100 x 109/L9 27 3.46 (2.23 – 5.38)*** - 2.38 (1.43 – 3.96)**
T-cell + WBC <100 x 109/L9 33 1.66 (1.05 – 2.64)* - 1.01 (0.60 – 1.69)
Pre-B + WBC ≥100 x 109/L9 45 1.22 (0.79 – 1.86) - 0.95 (0.61 – 1.49)
Initial risk group High Risk10 201 1.91(1.38 - 2.64)*** - -
Initial risk group Intermediate Risk10 154 1.10 (0.77 - 1.57) - -
Hazard ratio (HR) for death. Reference groups: 1late relapse, 2isolated extramedullary relapse, 3pre-B ALL, 4white blood cell count (WBC) <100 x 109/L at primary diagnosis, 5female,
6age <10 years at primary diagnosis, 7no detected or missing data on chromosomal abnormalities, 8not Down syndrome, 9pre-B + WBC <100 x 109/L at primary diagnosis, 10Standard
Risk patients according to the NOPHO ALL-92 and ALL-2000 protocols. *Unfavorable cytogenetics: MLL rearrangements n=7, hypodiploidy (modal chromosomal number <45) n=10,
t(9;22) n=5, t(1;19) n=6; Favorable cytogenetics: high hyperdiploidy (modal chromosomal number >50) n=106, t(12;21) n=67.  ***P<0.001, **P<0.01, *P<0.05.
Table 3. Relapse treatment for patients initially treated according to the NOPHO ALL-92 and NOPHO ALL-2000 protocols. 
Relapse Total NOPHO NOPHO CR2 rate HSCT 5-year 10-year
protocol n. ALL-92 ALL-2000 (%) in CR2** OS ± s.e % OS ± s.e %
(%) (%)* (%)* (%)
NOPHO HR arms 91 83 (26) 8 (5) 89 (98) 43 (47) 0.52 ± 0.05 0.45 ± 0.05
Standard-risk 57 (63) 53  4 57 (100) 27 (47) 0.70 ± 0.06 0.59 ± 0.07
High-risk 34 (37) 30 4 32 (94) 16 (47) 0.21 ± 0.07 0.21 ± 0.07
ALL-REZ BFM 289 198 (61) 91 (56) 261 (90) 113 (39) 0.57 ± 0.03 0.52 ± 0.03
Standard-risk 187 (65) 128 59 180 (96) 59 (32) 0.67 ± 0.04 0.63 ± 0.04
High-risk 102 (35) 70 32 81 (79) 54 (53) 0.37 ± 0.05 0.33 ± 0.05
RALLE*** 41 4 (1) 37 (23) 38 (93) 23 (56) 0.38 ± 0.08 0.38 ± 0.08
Standard-risk 18 (44) 3 15 18 (100) 7 (39) 0.49 ± 0.12 0.49 ± 0.12
High-risk 23 (56) 1 22 20 (87) 16 (70) 0.30 ± 0.10 0.30 ± 0.10
Other treatment 64 39 (12) 25 (16) 53 (83) 28 (44) 0.37 ± 0.06 0.37 ± 0.06
Standard-risk 31 (48) 17 14 28 (90) 15 (45) 0.55 ± 0.10 0.55 ± 0.10
High-risk 33 (52) 22 11 25 (81) 13 (41) 0.21 ± 0.07 0.21 ± 0.07
Total number 485 324 161 441 (91) 207 (43) 0.52 ± 0.02 0.47 ± 0.02
NOPHO High Risk (HR) arms,  ALL-REZ Berlin Frankfurt Münster (BFM) relapse protocols, Relapse in Acute Lymphoblastic Leukemia (RALLE) pilot protocol, “Other treatment”; com-
binations of protocols, the Children´s Cancer and Leukemia Group (CCLG) ALLR3 relapse protocol, Children´s Cancer Group (CCG) relapse protocols and non-protocol treatment.
Second complete remission (CR2), hematopoietic stem cell transplantation (HSCT). OS: overall survival; s.e.: standard error. *Proportion of relapsed patients within the primary pro-
tocol. ** Proportion of patients undergoing HSCT in CR2 within each relapse protocol. *** Patients with isolated extramedullary relapses were not enrolled in the study. 
Statistical analysis
Base-line variables were compared between the two up-front
protocols using Fisher´s exact tests for categorical variables and
the Mann-Whitney U test for continuous variables. In all survival
analyses, the time-scale was defined by the time of diagnosis of
relapse. Ten patients were lost to follow up, all in CR2 at the time
of last contact and with a median time of follow up of 8.2 years
(range 1.1-12.2 years). The Kaplan-Meier method was applied for
generating survival curves for event-free survival (EFS) and overall
survival (OS). Log rank test was used for comparing survival across
groups. Cox's proportional hazards regression models were used
for analysis of prognostic factors, estimating hazard ratios (HR)
with 95% confidence intervals. OS was defined as the period from
relapse diagnosis to death from any cause and censoring occurred
at the date of last known follow up. In the analysis of EFS, patients
were censored at the time of occurrence of the following second
events: last known follow up for patients alive in CR2, second
relapse, second malignancy (SMN), death caused by resistant dis-
ease or re-induction failure or death of undefined cause for
patients in CR2. Cumulative incidence curves of second events
were estimated by accounting for the competing nature of the sec-
ond events.26 The methods used for analyzing HSCT patients are
described in the Online Supplementary Appendix. All tests were two-
sided. P<0.05 were considered statistically significant. SPSS
Statistics software version 21.0 and STATA version 13 were used
for all statistical analyses.
Results
Patients' characteristics and second events
The characteristics and second events among patients
with ALL relapse are listed in Online Supplementary Tables
S1 and S2. Of the 103 patients with isolated
extramedullary relapses, 72 had isolated CNS relapses, 17
isolated testicular, three combined CNS and testicular, and
11 included other extramedullary sites (Online
Supplementary Tables S2). In total, 134 patients (28%) had
CNS involvement at relapse of which 30 (22%) were T-
cell lineage. Of the 104 patients with very early relapses,
89 (86%) were initially stratified as high or greater [68% if
classified as high-risk according to the National Cancer
Institute (NCI) risk groups]. The only statistically signifi-
cant differences in the relapse pattern between the up-
front protocols were the distribution of cytogenetic find-
ings (which can largely be explained by improvements in
the detection methods), and the distribution of second
events (which can partly be explained by the shorter fol-
low-up time for the ALL-2000 patients). Subsequent
relapse was the most common second event, occurring in
38% of patients. Second malignancies occurred in 11
patients of which 7 had undergone HSCT in CR2. 
To validate the commonly used risk classification sys-
tems, we retrospectively assigned relapse risk groups
according to the criteria in the new IntReALL trial and
compared the overall survival between the groups (Table
1). This risk-grouping is based on the CCLG and the BFM
risk categories. Patients with early combined pre-B ALL
relapses were stratified as standard-risk but the 5 year-OS
was only 38.0±10.6% (standard eror, s.e.). Fifteen of these
21 patients underwent HSCT in CR2.
In total, 57 patient with Down syndrome were treated
according to the NOPHO ALL-92 and ALL-2000 protocols
of which 18 relapsed (32%): 17 after chemotherapy only
and one after HSCT in CR1.  Twelve were initially treated
with the NOPHO ALL-92 protocol and 6 with the ALL-
2000 protocol. Fifteen patients were categorized as stan-
dard-risk at relapse, but even though 14 of them reached
CR2 and 3 subsequently underwent HSCT in CR2, only 3
survived long term. All deaths occured after second
relapse. 
Prognostic factors
Since we were studying a large cohort, we were able to
include a number of variables in the regression analysis.
The results of the Cox's proportional hazards regression
analysis for overall survival are presented in Table 2.
Primary risk groups were not included in the adjusted
models since we adjusted for base-line characteristics at
diagnosis. In the univariate analyses, age ten years or over
at primary diagnosis, T-cell immunophenotype, short time
in CR1, hyperleukocytosis at primary diagnosis, isolated
bone marrow relapse, and unfavorable cytogenetics were
adverse prognostic factors. In the first adjusted model,
Relapsed childhood ALL in the Nordic countries
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Table 4. Cox’s proportional hazards regression analysis of risk factors for overall survival in patients stratified as standard-risk at acute lym-
phoblastic leukemia relapse with HSCT in CR2 as a time-dependent covariate. 
Prognostic factors HSCT in CR2 Unadjusted model Adjusted model
/total (%) HR (95% CI) HR (95% CI)
HSCT in CR21 108/283 (38%) 2.94 (1.90 – 4.53)*** 2.82 (1.80 – 4.53)***
Male2 68/179 (38%) 0.70 (0.47 – 1.04) 1.29 (0.85 – 1.94)
Age ≥ 10 years 
at primary diagnosis3 28/46 (61%) 1.76 (1.10 – 2.81)* 1.39 (0.85 – 2.29)
WBC ≥ 100 x 109/L
at primary diagnosis4 11/21 (52%) 1.11(0.54 – 2.30) 1.02 (0.49 – 2.15)
Unfavorable cytogenetics5 2/8 (25%) 2.17 (0.91 – 5.20) 2.15 (0.88 – 5.25)
Favorable cytogenetics5 33/117 (28%) 0.89 (0.56 – 1.43) 1.11 (0.68 - 1.83)
Other cytogenetics5 27/63 (43%) 1.23 (0.73 – 2.10) 1.27 (0.74 – 2.16)
Hazard ratio (HR) for death. Number of patients included in regression models n=283, number of observations n=417. Patients that did not achieve CR2 were excluded from the
model (n=10). Reference groups: 1chemotherapy only, 2female, 3age <10 years at primary diagnosis, 4white blood cell count (WBC) <100 x 109/L at primary diagnosis, 5missing data
or no detected chromosomal abnormalities. Unfavorable cytogenetics: MLL rearrangements, hypodiploidy (modal chromosomal number <45), t(9;22), t(1;19).  Favorable cytogenet-
ics: high hyperdiploidy (modal chromosomal number >50) and t(12;21).
T. Oskarsson et al.
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Table 5. Reported outcomes of trials and cohorts in relapsed childhood acute lymphoblastic leukemia. 
Relapse treatment Relapse period Risk group or N. of patients Survival ± s.e.
type of relapse
Non-uniform relapse treatment
aNOPHO4 1981-1993 All risk groups 315 11-year OS 33% ± 3
11-year EFS 28% ± 3
NOPHO 1992-2001 All risk groups 246 5-year OS 45% ± 3
5-year EFS 36% ± 3
NOPHO 2002-2011 All risk groups 239 5-year OS 58% ± 3
5-year EFS 51% ± 3
bCOG29 1988-2002 All risk groups 1961 5-year OS 36% ± 2
cCOG28 1996-2003 All risk groups 347 3-year OS 56% ± 3
3-year EFS 45% ±3
Non-randomized trials
MRC UKALL R149 1991-1995 All risk groups 256 5-year EFS 46% ± 3
CCLG ALL R27 1995-2002 All risk groups 150 5-year OS 56% ± 4
5-year EFS 47% ± 4
RALLE Pilot13 2004-2010 BM involving 40 5-year OS 37% ± 8
5-year EFS 37% ± 8
dCOPRALL-9750 1997-2002 Pre-B iEM relapses 68
Time in CR1 <24 months 35 4-year OS 40% ± 8
4-year EFS 31% ±   8
Time in CR1  ≥24 months 34 4-year OS 76% ± 7
4-year EFS 61% ±8
ALL-REZ BFM 95/969 1995-2001 eIntermediate risk
MRD <10-3 after induction 46 10-year OS 91% ± 4
10-year EFS 76% ± 6
MRD ≥10-3 after induction 34 10-year OS 32% ± 8 
10-year EFS 18% ± 7
ALL-REZ BFM 20028 2002-2009 eIntermediate risk 208
Continuation chemotherapy  109 8-year OS 73% ± 7
if MRD <10-3 after induction 8-year EFS 70% ± 5
HSCT in CR2 99 8-year OS 68% ±   5
if MRD ≥10-3 after induction 8-year EFS 64% ± 5
Trials with randomizations
ALL-REZ BFM 8710 1987-1990 All risk groups 183 15-year OS 37% ± 3
15-years EFS 30% ± 3
Timing of ARA-C and Very early
MTX during induction and early BM 41 NS
involving relapses
ALL-REZ BFM 9012 1990-1995 All risk groups 525 10-year OS 36% ± 2
10-year EFS 30% ± 2
MTX 1g/m2/36 hours vs. Pre-B iEM, pre-B early 269 NS
MTX 5g/m2/24 hours and late relapses  
CCLG ALL R311 2003-2009 All risk groups 212 3-year OS 57% ± 4
3-year PFS 50% ± 4
Idarubicin in induction All risk groups 109 3-year OS 45% ± 5 
3-year PFS 36% ± 5 
Mitoxantrone in induction All risk groups 103 3-year OS 69% ± 5
3-year PFS 65% ± 5
Nordic Society of Paediatric Haematology and Oncology (NOPHO), Children´s Oncology Group (COG), Medical Research Council (MRC). Children’s Cancer and Leukemia Group
(CCLG), Relapse in Acute Lymphoblastic Leukemia (RALLE) pilot, Berlin Frankfurt Münster (BFM). CR1: first complete remission; MRD: minimal residual disease; HSCT in CR2:
hematopoietic stem cell transplantation in second complete remission; ARA-C: cytarabine; MTX: methotrexate; BM: bone marrow; iEM: isolated extramedullary. Very early relapse:
occurring <18 months from primary diagnosis. Early relapse: occurring ≥18 months from diagnosis and <6 months after completion of primary therapy. Late relapse: occurring ≥ 6
months after completion of primary therapy. OS: overall survival; EFS: event-free survival; pFS: progression-free survival; NS: no statistically significant difference. If standard error
(s.e.) was not available it was derived from the reported 95% confidence interval.  aIncludes patients who underwent HSCT in CR1 (n=65, 45 allogenic and 19 autologous). In 1993,
6 NOPHO patients relapsed and are were included in both studies involving the 1981-1993 and 1992-2001 periods. bPatients enrolled in Children’s Cancer Group (CCG) trials 1988-
2002 for initial treatment but non-uniform relapse treatment. cPatients enrolled in the CCG-1952 study for initial treatment, only standard risk ALL (WBC <50x109/L and age 1 to 9
years) but non-uniform relapse treatment. dPatients with early relapses (time in CR1 <24 months) were treated with VANDA induction and block therapy followed by HSCT in CR2
if donor available but patients with late relapses (time in CR1 ≥24 months were treated with block therapy followed by radiotherapy and maintenance. eIntermediate risk (S2): pre-
B early or late combined bone marrow relapse, pre-B late isolated bone marrow relapse, pre-B or T-cell very early and early isolated extramedullary relapse. 
time to relapse (worse if earlier), site of relapse (worse if
involving the bone marrow), age ten years or over at pri-
mary diagnosis, unfavorable cytogenetics and Down syn-
drome were all statistically significant independent prog-
nostic factors. Adding up-front or relapse protocol to the
adjusted model did not generate significant HRs or result
in any notable change in the HRs of the other co-variates
in the models. Immunophenotype is commonly used in
the risk assessment at relapse, but although immunophe-
notype was a risk factor in the univariate analysis, it was
not in the multivariate analysis. In the second adjusted
model, we added an interaction variable combining
immunophenotype and WBC at diagnosis and found that
T-cell lineage disease with hyperleukocytosis at primary
diagnosis (n=27; 24 high-risk, 3 standard risk) was a
notable independent risk factor for survival after relapse,
HR 2.38 (95%CI: 1.43-3.96; P=0.001). We analyzed sepa-
rately the standard-risk group and adjusted for sex, age,
Down syndrome and cytogenetics (data not shown). For the
standard-risk group, age ten years or over HR 1.99 (1.24-
3.21; P=0.004) and Down syndrome, HR 4.70 (2.46-8.94;
P<0.001) were both independent prognostic factors for
overall survival.   
Survival analysis
In the whole study population, the 5-year EFS was
43.7±2.3% and the 5-year OS was 51.5±2.3%. At five
years, the EFS for the ALL-92 patients was 42.1±2.7% and
the OS was 49.8±2.8% but 46.8±4.2 and 52.7±4.4% for
the ALL-2000 patients, respectively. To investigate if there
was a generally improved prognosis over time, the
patients were divided into two relapse periods, 1992-2001
(n=239) and 2002-2011 (n=246), approximately correspon-
ding to the timing of the introduction of more general
MRD measurements in the Nordic countries. 
Both OS and EFS were markedly higher for patients
who relapsed between the years 2002-2011 compared to
1992-2001 (Figure 1A and B). HR for death was 0.62 (0.48-
0.80; P<0.001) for 2002-2011 but for second events the HR
was 0.64 (0.51-0.82; P<0.001). We compared the cumula-
tive incidence of second events between the two relapse
periods and found a reduction of second relapses in the
later period (Figure 1C). There were no statistically signif-
icant differences between the time periods for the other
second events. Looking for a possible explanation for
these differences, we compared the pattern of relapse
between the two time periods and observed a difference
in the time distribution of relapses (Online Supplementary
S3). In 1992-2001, 26.8% of relapses occurred very early,
32.6% early, and 40.6% late, but between 2002 and 2011,
16.3% occurred very early, 28.9% early, and 54.9% late
(P=0.002).
Relapse treatment
The ALL-REZ BFM protocols were the most commonly
used treatment for ALL relapse (60%) (Table 3). The pro-
portion of patients receiving BFM treatments was rela-
tively stable over the whole study period but the propor-
tion of patients receiving NOPHO treatment was much
lower in the later part of the study period (no patient
after 2005). In addition, 8 patients were treated with the
CCLG’s ALLR3 protocol 2009-2011. The CR2 rate for the
whole study period was 91%: 97% for standard-risk
relapses and 82% for high-risk relapses. The CR2 rate for
isolated extramedullary relapses was 95% and 90% for
bone marrow relapses, but only 71% for very early bone
marrow relapses, compared to 97% for late bone marrow
relapses. There was no significante difference in CR2 rate
between the two primary protocols, relapse periods or
specific relapse protocols. We did not observe a statisti-
cally significant difference in overall survival between the
relapse protocols used during the study period (Table 3). 
Hematopoietic stem cell transplantation     
Hematopoietic stem cell transplantation in CR2 was
performed in 207 of the 485 patients (43%) included in
the study: 137 of 324 ALL-92 patients (42%) and 70 of
161 ALL-2000 patients (44%). The allocation to HSCT
was 43% (102 of 239) during 1992-2001 and 43% (105 of
246) during 2002-2011. The proportion of standard-risk
patients allocated to HSCT was slightly higher in the
period 1992-2001 (41% vs. 34%) but the proportion of
high-risk patients allocated to HSCT increased from 45%
Relapsed childhood ALL in the Nordic countries
haematologica | 2016; 101(1) 73
Figure 1. Comparison of relapse periods 1992-2001 and 2002-2011. (A)
Overall survival after relapse. (B) Event-free survival after relapse. (C)
Cumulative incidence of second relapse using competing risks.
A
B
C
during the period 1992-2001 to 61% during the period
2002-2011. 
As expected, OS for high-risk patients was markedly
higher if HSCT was performed in CR2, 46.7±5.1% com-
pared to 25.0±6.0% (P<0.001). Interestingly, we observed
the opposite association in the standard-risk group in
which the overall survival was 61.1±4.8% for patients
allocated to HSCT in CR2 compared to 74.5±3.6%
(P=0.02) if continuation chemotherapy was used for con-
solidation. We investigated the effect of HSCT in CR2 on
survival in the standard-risk group further in a time-depen-
dent regression model and found a HR for the HSCT
group of 2.94 (95%CI: 1.90-4.53) (Table 4). Adjusting for
other non-stratifying base-line variables neither changed
the HRs significantly (2.82; 95%CI: 1.80-4.41) nor yielded
additional co-variates with a statistically significant and
independent association with prognosis. Since there were
only 3 patients with T-cell immunophenotype plus hyper-
leukocytosis in the standard-risk group, this variable was
not included in the model as a single co-variate. Of the 27
patients with T-cell disease and hyperleukocytosis, 13
underwent HSCT in CR2 but only 4 survived (15%).  
Discussion
Relapse of ALL is still one of the most common child-
hood cancer subgroups with an incidence similar to rhab-
domyosarcoma and nephroblastoma (Wilms tumor).27
Despite the vast improvement in outcome after up-front
ALL treatment, the increase in survival after relapse has
not been as pronounced.4,7,10-12,28 In this study, an improve-
ment in OS over time was observed and is now close to
60%. Table 5 summarizes the reported results in relapsed
childhood ALL from multicenter trials and cohorts over
the last three decades. 
At present, patients with relapsed ALL are allocated to
different risk groups based on the immunophenotype, the
time from primary diagnosis to relapse and the anatomic
site of relapse. But unlike the risk stratification at primary
diagnosis, cytogenetics are not used to individualize the
treatment intensity. We demonstrate that unfavorable cyto-
genetics, age ten years or over, T-cell immunophenotype
with hyperleukocytosis and Down syndrome were all addi-
tional individual prognostic factors in relapsed ALL. 
The time from diagnosis to relapse is the strongest
known individual risk factor for overall survival.4,29 Nearly
90% of patients with very early relapses were stratified as
high-risk or greater at initial diagnosis indicating that clin-
ical and genetic features present at diagnosis affect sur-
vival after relapse.30,31 In this study, two-thirds of the T-cell
relapses occurred within 18 months, but contrary to previ-
ous findings, immunophenotype was not an individual
prognostic factor for OS since it was over-ruled by other
co-variates in the adjusted regression analysis.
Interestingly, the interaction between WBC at diagnosis
and T-cell immunophenotype created a strong prognostic
variable. Only 4 out of 27 (15%) patients with T-cell
immunophenotype and hyperleukocytosis survived long-
term despite the use of HSCT in CR2 in 13 (48%) of them.
However, this risk factor may be of limited additional
value since with the current risk stratification, the majority
of these patients are categorized as high-risk at relapse. 
Children with Down syndrome  have both an increased
risk of developing ALL32 and an increased risk of treat-
ment-related toxicity during primary ALL treatment.23-25,33
Historically, Down syndrome ALL (DS-ALL) has been
associated with inferior outcome, both with regard to OS
and EFS.34,35 In this study, DS-ALL was associated with
very poor outcome, irrespective of the time period (early
vs. late period) and the fact that most of these patients
were stratified as standard-risk. Second relapses were the
most common reason for treatment failure, indicating that
patients with relapsed DS-ALL might have been treated
with less intensive post-induction regimens to minimize
the risk of treatment toxicity but subsequently failed to
remain in long-term second remission.36 In a study by
Meyr et al., children with DS had worse outcome after
relapse mainly because of increased toxicity rather than
subsequent relapse, but if the relapse occurred after the
year 2000 this difference was not maintained.35
Adverse clinical factors, such as the time to relapse,
age37,38 and WBC39 and cytogenetic risk factors,17,18,20 are
most likely surrogate markers for underlying submicro-
scopic genetic abnormalities.40-42 With increased under-
standing of the biology of ALL, genetic factors are expect-
ed to be included in the future risk stratification and serve
as targets for novel therapies.43-45   
Despite the adjustments made to the NOPHO ALL-2000
protocol, OS did not differ significantly from the ALL-92
protocol: 5-year OS 89.1±1.1% and 87.6±0.8%, respec-
tively.1 Although the relapse rate was lower after the ALL-
2000 treatment, it is expected that some of the late relaps-
es from the ALL-2000 era are yet to occur. Although the
pattern of relapse and outcome after relapse was very sim-
ilar between the two NOPHO protocols, we observed a
significant improvement in outcome for relapses occurring
between 2002 and 2011 compared to 1992-2001, as well
as a lower proportion of relapses generally associated with
worse outcome (very early and early relapses) in the later
period. In addition, we did not find a statistically signifi-
cant difference in the CR2 rate or survival between the
relapse protocols used during the study period, which sup-
ports the view that factors other than the protocol used
explain the survival improvement and the changes in the
relapse pattern between the two time periods. Minimal
residual disease was measured in 73% of patients during
the NOPHO ALL-2000 trial. However, although it was not
used for risk stratification, it was optional to proceed to
HSCT if MRD was 10-3 % or over after three months of
treatment.1 The retrospective study design and the lack of
detailed MRD-data in our cohort constitute a drawback,
but to estimate the effect of MRD on survival in general
we compared outcomes before and after the year 2002,
roughly coinciding with the general introduction of MRD
analysis in most Nordic childhood cancer centers. The use
of MRD in the assessment of treatment response after re-
induction and preceding allogeneic HSCT in CR2 was
obligatory in the ALL-REZ BFM 2002 and RALLE proto-
cols. However, although not obligatory in the NOPHO
ALL-2000 HR protocol, it was still available in many cen-
ters, since evidence at that time supported the stratifica-
tion by MRD over morphology.46-48 Therefore, after 2002
non-high-risk patients with high MRD levels after re-
induction were recommended to undergo allogeneic
HSCT in CR2 and a larger proportion of the high-risk
patients was likely to be disease-free preceding HSCT.16,21
The introduction of MRD could, therefore, be one of the
explanations for the observed overall reduction of first and
second relapses over time. 
T. Oskarsson et al.
74 haematologica | 2016; 101(1)
Our results indicate that patients stratified as standard-
risk at relapse have worse OS after HSCT in CR2 com-
pared to chemotherapy only. Although we adjusted for
base-line variables such as age, WBC at diagnosis and
cytogenetics, this survival difference remained clearly sig-
nificant. However, this may reflect the fact that those
patients selected for HSCT had a higher risk based on the
MRD response after re-induction. This would result in a
selection of patients with a higher risk of death to the
HSCT group and MRD negative patients to the
chemotherapy group. Previous studies have shown supe-
rior outcome after HSCT in CR2 for MRD positive stan-
dard-risk patients,8,9 but in this study we did not find other
risk factors or subgroups that seem to benefit from HSCT
in CR2. Furthermore, the overall outcome of the SCT-
group improved in the second time-period, when MRD
was presumably available speaking against this type of
negative selection (data not shown).
From 2015, the new international trial, IntReALL, will
be the treatment of choice for relapsed childhood ALL in
the Nordic countries. Our results indicate that the risk
classification used in IntReALL is a reasonable approach,
but we question whether early combined pre-B relapses
should be classified as standard-risk instead of high-risk,
since the 5-year overall survival for this subgroup was
only 38.0% (±10.6%), despite the fact that 14 of the 21
patients underwent HSCT in CR2. In the ALL-REZ BFM
2002 protocol, intermediate-risk patients with high MRD
levels after re-induction have been recommended to
undergo allogeneic HSCT in CR2 if a donor is available.
With these adjustments, the outcome for both good and
poor responders has been similar (approximately 70%
long-term OS), but the outcome for patients with early
combined pre-B relapses has remained poor.8 
Conclusion
Over recent decades, improvements in the NOPHO ALL
treatment have caused a reduction in the relapse rate.
However, although improved survival over time was
observed in this study, OS, especially for the high-risk
patients, is still relatively poor. Most patients achieve sec-
ond complete remission regardless of treatment protocol.
But despite current treatment modalities, one-third of
patients suffer second relapse. Therefore, better consolida-
tion methods are needed without increasing the burden of
treatment toxicities. Tailored risk-adapted treatment is the
cornerstone of modern relapse therapy, but there is an
urgent need for the development of new drugs and target-
ed therapies. There have been few reports on randomized
controlled trials in patients with relapsed childhood ALL,
and with the numbers of relapse patients decreasing, an
international collaboration is very important to serve as a
platform for progress to be made in the treatment of
relapsed childhood ALL. 
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